Swedish Orphan Biovitrum AB (Sobi) (STO:SOBI), a specialised international biopharmaceutical company focused on treatment of rare diseases, announced on Wednesday that it will commence a short-term clinical study to evaluate the efficacy and safety of anakinra and emapalumab in the treatment of hyper-inflammatory syndrome, one of the most serious complications associated with severe COVID-19 disease.
Reportedly, this is in response to a request from the National Institute for Infectious Diseases, the organisation which is acting as the coordinating site for the SARS-CoV-2 epidemic in Italy.
These products, which are currently used in the treatment of rare diseases, have been considered for investigation as a result of emerging data and observations made by Italian physicians treating patients with COVID-19. A summary of the study protocol will be published on clinicaltrials.gov.
Patients who are treated or who may need treatment with emapalumab and anakinra for approved indications will not be impacted, the company added.
Sobi provides sustainable access to innovative therapies in the areas of haematology, immunology and specialty indications.
Poolbeg PHarma plc receives notice of allowance for POLB 001 patent
RedHill Biopharma secures USPTO Patent for Talicia, extending protection through 2034
Micron Biomedical names new scientific advisor to CEO
Quanterix partners with leading health networks for Alzheimer's diagnosis advancements
Precision BioSciences reports FDA pre-IND feedback for PBGENE-HBV
VBI to sell manufacturing capabilities and enter new license agreement with Brii Biosciences
Ondine Biomedical's Steriwave shows promise in nasal pathogen reduction
BioSenic expands patent coverage for ATO therapeutic platform
PacBio unveils Nanobind PanDNA kit for enhanced DNA extraction solutions
Sequentify receives funding from Israel Innovation Authority
INOVIO plans BLA submission for INO-3107 as RRP treatment
ImmunityBio secures USD320m investment from Oberland Capital
Poolbeg Pharma prioritises promising RSV drug candidates identified through AI-led analysis
GHIT fund invests JPY500m in antimalarial drug clinical trial